United States Policy Implications of Generic Substitution of Branded Human Immunodeficiency Virus Medications

Hogue, S., Brogan, A., & Goodwin, B. (2013). United States Policy Implications of Generic Substitution of Branded Human Immunodeficiency Virus Medications. Value in Health, 16(7), A364-A365.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Treatment preferences among patients with mild-to-moderate atopic dermatitis
Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Spatiotemporal analysis exploring the effect of law enforcement drug market disruptions on overdose, Indianapolis, Indiana, 2020-2021
Article

Protocol for the formative phase of a trial (SHE-CAN) to test co-designed implementation strategies for HPV-based cervical screening among vulnerable women in two diverse settings in India